PAVmed Inc. reported a non-GAAP adjusted loss of approximately $0.4 million, or $(0.02) per common share, for the third quarter ended September 30, 2025. Cash and cash equivalents stood at $3.1 million as of September 30, 2025, compared to $1.2 million as of December 31, 2024. During the period, Veris Health launched the commercial phase of its strategic partnership and resumed development of its implantable physiological monitor. PAVmed also signed a letter of intent to license new endoscopic esophageal imaging technology.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-022122), on November 13, 2025, and is solely responsible for the information contained therein.